CERo Therapeutics Holdings, Inc.
CERO · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | -$0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | -100% | – |
| Gross Profit | $0 | -$0 | -$0 | $0 |
| % Margin | – | – | – | 50% |
| EBITDA | -$0 | -$0 | -$0 | $0 |
| % Margin | – | – | – | 132.9% |
| Net Income | -$0 | -$0 | -$0 | $0 |
| % Margin | – | – | – | 107% |
| EPS Diluted | -9.1 | -61.71 | -3.18 | 0.56 |
| % Growth | 85.3% | -1,840.6% | -667.9% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | $0 |
| Capital Expenditures | $0 | $0 | $0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | $0 |